SecSonar.com

Grifols, S.A. (GRFS)

Grifols, S.A. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Grifols, S.A. (GRFS) is a Drug Manufacturers - General company based in ES with a market capitalization of $6.7B. Revenue grew 0.2% year-over-year and the company generated $859.3M in free cash flow. This page tracks GRFS's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

ES · 23.83K employees · IPO Jun 2, 2011

Valuation

Valuation & price

$8.03 · as of May 26, 2026 · -26.0% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

—

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$10.72$8.94$7.16Jul 25Dec 25Jul 26Jul 7, 25$8.87Jul 9, 25$9.39Jul 11, 25$9.74Jul 15, 25$9.77Jul 17, 25$10.05Jul 21, 25$10.00Jul 23, 25$9.85Jul 25, 25$10.10Jul 29, 25$10.50Jul 31, 25$10.70Aug 4, 25$10.72Aug 6, 25$10.48Aug 11, 25$10.60Aug 13, 25$10.64Aug 15, 25$10.72Aug 19, 25$10.19Aug 21, 25$10.08Aug 25, 25$9.82Aug 27, 25$9.80Aug 29, 25$9.97Sep 3, 25$9.59Sep 5, 25$10.13Sep 9, 25$9.88Sep 11, 25$10.04Sep 16, 25$9.83Sep 18, 25$9.82Sep 22, 25$9.70Sep 24, 25$9.86Sep 26, 25$9.82Sep 30, 25$9.96Oct 2, 25$10.02Oct 6, 25$9.61Oct 8, 25$9.63Oct 10, 25$9.32Oct 14, 25$9.58Oct 16, 25$9.75Oct 21, 25$9.34Oct 23, 25$9.55Oct 27, 25$9.38Oct 29, 25$9.39Oct 31, 25$9.37Nov 4, 25$9.22Nov 6, 25$8.36Nov 10, 25$8.60Nov 12, 25$8.69Nov 14, 25$8.71Nov 18, 25$8.60Nov 20, 25$8.43Nov 25, 25$8.67Nov 28, 25$8.85Dec 2, 25$8.51Dec 4, 25$8.89Dec 8, 25$8.98Dec 10, 25$8.95Dec 12, 25$9.14Dec 16, 25$8.96Dec 18, 25$8.92Dec 22, 25$9.08Dec 24, 25$9.03Dec 29, 25$9.12Jan 2, 26$9.24Jan 6, 26$9.19Jan 8, 26$9.49Jan 12, 26$9.14Jan 14, 26$9.24Jan 16, 26$8.89Jan 21, 26$9.02Jan 23, 26$9.22Jan 27, 26$9.29Jan 29, 26$9.29Feb 2, 26$9.40Feb 4, 26$9.54Feb 9, 26$9.58Feb 11, 26$9.21Feb 13, 26$9.32Feb 18, 26$9.72Feb 20, 26$9.40Feb 24, 26$9.07Feb 26, 26$8.96Mar 2, 26$9.09Mar 4, 26$8.66Mar 6, 26$8.59Mar 10, 26$8.20Mar 12, 26$7.97Mar 17, 26$8.02Mar 19, 26$7.77Mar 23, 26$7.69Mar 25, 26$7.71Mar 27, 26$7.49Mar 31, 26$8.02Apr 2, 26$8.24Apr 7, 26$8.10Apr 9, 26$8.05Apr 13, 26$8.36Apr 15, 26$8.69Apr 17, 26$8.75Apr 22, 26$8.39Apr 24, 26$8.08Apr 28, 26$8.07Apr 30, 26$8.24May 4, 26$8.23May 6, 26$8.41May 8, 26$8.10May 12, 26$7.56May 14, 26$7.79May 18, 26$7.87May 20, 26$8.19May 22, 26$7.98May 28, 26$7.98Jun 1, 26$7.74Jun 3, 26$7.47Jun 5, 26$7.64Jun 9, 26$7.34Jun 11, 26$7.49Jun 15, 26$7.62Jun 17, 26$7.46Jun 22, 26$7.28Jun 24, 26$7.22Jun 26, 26$7.39Jul 2, 26$7.16
$7.0852-week range$10.85
Loading valuation history…

Fundamentals

Key fundamentals

$6.7B

Market cap

0.2%

Revenue growth (YoY)

35.7%

Gross margin

$859.3M

Free cash flow (USD)

$7.9B

Net debt

0.1%

Share dilution

3/6

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$4.0BFY 2017$4.3BFY 2018$4.5BFY 2019$5.1BFY 2020$5.3BFY 2021$4.9BFY 2022$6.1BFY 2023$6.6BFY 2024$7.2BFY 2025$7.2B
$4B$7.2B

Free cash flow by year

2016 → 2025

FY 2016$260.6MFY 2017$518.8MFY 2018$429.7MFY 2019$156.6MFY 2020$830.2MFY 2021$349.6MFY 2022$-386.4MFY 2023$-91.6MFY 2024$530.8MFY 2025$751.1M
$260.6M$751.1M

Gross margin by year

2021 → 2025

FY 202139.8%FY 202236.5%FY 202337.7%FY 202438.8%FY 202535.7%
39.8%35.7%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 6-K filed Jun 18, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 6-K filingManagement ChangeJun 22, 2026Filing
  • Annual reportAnnual Report FiledJun 18, 2026Filing
  • Annual reportAnnual Report FiledMay 15, 2026Filing
  • Annual reportAnnual Report FiledMay 7, 2026Filing
  • Annual report20-F FiledApr 17, 2026Filing
  • Annual reportAnnual Report FiledApr 14, 2026Filing

Questions

Frequently asked questions

What is Grifols, S.A.'s market cap?

Grifols, S.A. (GRFS) has a market capitalization of $6.7B.

What is GRFS's P/E ratio?

A meaningful P/E ratio is not available for GRFS — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

Are insiders buying GRFS stock?

SEC Form 4 filings show no open-market insider buys at Grifols, S.A. in the last 90 days (0 sells).

Same arena

Related companies in Drug Manufacturers - General

OGN

Organon & Co.

$3.5B

SCLX

Scilex Holding Company

$79M

SRXH

SRx Health Solutions Inc.

$3.9M

BIIB

Biogen Inc.

$29.2B

ZTS

Zoetis Inc.

$32.6B

GSK

GSK plc

$101.9B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.